Hubert T. Faber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hubert T. Faber has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Cor W. R. J. Cremers
3 shared publicationsMaarten J. F. de Wolf
3 shared publicationsAd F. M. Snik
2 shared publicationsMyrthe K. S. Hol
Radboud University Nijmegen Medical Centre
2 shared publicationsCatharina A. J. Dun
Department of Otorhinolaryngology, Donders Centre of Neuroscience, Radboud University Medical Centre Nijmegen, The Netherlands
1 shared publicationHanneke Kievit
1 shared publication
Latest Publications
- Open Access
- 1 December 2012
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 138 (12) , 1129-1135
Analysis of Factors Predicting the Success of the Bone Conduction Device Headband Trial in Patients With Single-Sided Deafness
For several years, bone conduction devices (BCDs), including both the Cochlear Ltd bone-anchored hearing aid (BAHA) and, more recently, the Oticon Medical devices (Ponto) have been used as contralateral routing of sound (CROS) devices. A group of patients who benefit from this rehabilitation have unilateral sensorineural hearing loss, commonly known as single-sided deafness (SSD). Quiz Ref IDThe BCD CROS achieves significant improvement concerning some problems caused by the head shadow effect, which plays a substantial role in the hearing impairment of patients with SSD.1,2 Subjective benefit analysis by means of the Abbreviated Profile of Hearing Aid Benefit (APHAB)3 shows a significant improvement in the ease of communication, conversation in background noise, and conversations with reverberation.4-6 However, it remains difficult to predict which patients with SSD will benefit from BCD CROS treatment. All patients receiving the standard workup for BCD CROS treatment have the opportunity to try a BCD headband to help them decide whether to proceed to BCD surgery. According to studies by Andersen et al7 and Schrøder et al,8 only 20% to 25% of the patients with SSD caused by acoustic neuroma surgery opt for a percutaneous BCD CROS. Quiz Ref IDDesmet et al9 evaluated 196 patients with SSD for several factors (Fletcher index of ipsilateral and contralateral ear, bone conduction threshold [0.5, 1, and 2 kHz], etiology, age, and duration of deafness) to determine their influence on the decision of a patient to opt for a BCD or not. Eighty-seven patients (44%) opted for a BCD, but no statistically significant factors were found. Kompis et al10 also searched for predicting factors such as age, sex, transcranial attenuation, and duration of deafness in 46 patients with SSD. The decision of the 29 patients who opted for a BCD (63%) was based on subjective factors.
- 1 December 2012
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 138 (12) , 1129-1135
Open AccessAnalysis of Factors Predicting the Success of the Bone Conduction Device Headband Trial in Patients With Single-Sided Deafness
For several years, bone conduction devices (BCDs), including both the Cochlear Ltd bone-anchored hearing aid (BAHA) and, more recently, the Oticon Medical devices (Ponto) have been used as contralateral routing of sound (CROS) devices. A group of patients who benefit from this rehabilitation have unilateral sensorineural hearing loss, commonly known as single-sided deafness (SSD). Quiz Ref IDThe BCD CROS achieves significant improvement concerning some problems caused by the head shadow effect, which plays a substantial role in the hearing impairment of patients with SSD.1,2 Subjective benefit analysis by means of the Abbreviated Profile of Hearing Aid Benefit (APHAB)3 shows a significant improvement in the ease of communication, conversation in background noise, and conversations with reverberation.4-6 However, it remains difficult to predict which patients with SSD will benefit from BCD CROS treatment. All patients receiving the standard workup for BCD CROS treatment have the opportunity to try a BCD headband to help them decide whether to proceed to BCD surgery. According to studies by Andersen et al7 and Schrøder et al,8 only 20% to 25% of the patients with SSD caused by acoustic neuroma surgery opt for a percutaneous BCD CROS. Quiz Ref IDDesmet et al9 evaluated 196 patients with SSD for several factors (Fletcher index of ipsilateral and contralateral ear, bone conduction threshold [0.5, 1, and 2 kHz], etiology, age, and duration of deafness) to determine their influence on the decision of a patient to opt for a BCD or not. Eighty-seven patients (44%) opted for a BCD, but no statistically significant factors were found. Kompis et al10 also searched for predicting factors such as age, sex, transcranial attenuation, and duration of deafness in 46 patients with SSD. The decision of the 29 patients who opted for a BCD (63%) was based on subjective factors.
- 19 August 2012
- Published by Springer Nature
- Vol. 270 (4) , 1285-1291
Benefit of Baha in the elderly with single-sided deafness
The objective of this study is to determine the benefits of bone-anchored hearing aid (Baha) contralateral routing of signal (CROS) in the older adult population with single-sided deafness. Five questionnaires [general usage questionnaire, Glasgow benefit inventory (GBI), Abbreviated profile of hearing aid benefit (APHAB), Nijmegen cochlear implant questionnaire and the hearing handicap inventory for the elderly-screening version (HHIE-S)] were used to evaluate Baha use. Consecutive patients over 60 years of age with SSD fitted with a Baha CROS between April 1990 and April 2007 not using a conventional hearing aid in the better-hearing ear were identified. Nine out of 11 patients (82 %) were still using their Baha CROS, and 7 of the 11 patients (64 %) were still satisfied. The patients experienced no to little problems with handling and cleaning of the device. The GBI scores show good benefit in domains total (14 ± 11) and general (19 ± 17). The APHAB shows that, overall, 3 out of the 11 patients (27 %) experienced significant benefit, while all others experienced no significant benefit and no drawbacks. The HHIE-S shows that the patients experienced severe (18 %), mild to moderate (46 %) or no handicap (36 %) when using the Baha CROS. In conclusion, the benefit of a Baha CROS for elderly patients with SSD is evident in the majority of patients.
- 19 August 2012
- Published by Springer Nature
- Vol. 270 (4) , 1285-1291
Benefit of Baha in the elderly with single-sided deafness
The objective of this study is to determine the benefits of bone-anchored hearing aid (Baha) contralateral routing of signal (CROS) in the older adult population with single-sided deafness. Five questionnaires [general usage questionnaire, Glasgow benefit inventory (GBI), Abbreviated profile of hearing aid benefit (APHAB), Nijmegen cochlear implant questionnaire and the hearing handicap inventory for the elderly-screening version (HHIE-S)] were used to evaluate Baha use. Consecutive patients over 60 years of age with SSD fitted with a Baha CROS between April 1990 and April 2007 not using a conventional hearing aid in the better-hearing ear were identified. Nine out of 11 patients (82 %) were still using their Baha CROS, and 7 of the 11 patients (64 %) were still satisfied. The patients experienced no to little problems with handling and cleaning of the device. The GBI scores show good benefit in domains total (14 ± 11) and general (19 ± 17). The APHAB shows that, overall, 3 out of the 11 patients (27 %) experienced significant benefit, while all others experienced no significant benefit and no drawbacks. The HHIE-S shows that the patients experienced severe (18 %), mild to moderate (46 %) or no handicap (36 %) when using the Baha CROS. In conclusion, the benefit of a Baha CROS for elderly patients with SSD is evident in the majority of patients.
- 1 August 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (6) , 1013-1017
Titanium Fixtures for Bone-Conduction Devices and the Influence of Type 2 Diabetes Mellitus
Objective The aim of this study is to evaluate whether diabetes mellitus (DM) is a risk factor for titanium fixture loss in bone-conduction devices (BCDs) because of osseointegration failure. Study Design Retrospective case study. Setting Tertiary referral center. Patients All patients who received a BCD at Nijmegen between January 1, 1988, and December 31, 2007, were analyzed. The analyses were performed on 833 patients (993 implants) and a subpopulation of patients aged 40 years or older consisting of 641 patients (739 implants). Methods Patients received a questionnaire asking about the presence of DM at the time of implantation. Data concerning implant loss were retrieved from medical records and the Nijmegen BCD database. Results The total survival rate of the BCD implant in this population was 90.6%. The prevalence of DM was 9.3%. In the subpopulation of patients aged 40 years or older, the non-DM group lost 5.1% of their implants versus 14% of Type 2 DM patients, a statistically significantly difference (p = 0.003). Spontaneous loss, loss due to a Grade 4 Holgers skin reaction, and trauma accounted for 2.2% versus 4.7% (p = 0.13), 0.5% versus 2.3% (p = 0.1), and 0.6% versus 4.7% (p = 0.007), respectively, of implant losses in non-DM versus Type 2 DM patients. Conclusion The prevalence of DM among the Nijmegen BCD population is higher than the general Dutch prevalence. A statistically significantly higher implant loss was observed during the study period for Type 2 DM patients than non-DM BCD wearers.
- 1 August 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (6) , 1013-1017
Titanium Fixtures for Bone-Conduction Devices and the Influence of Type 2 Diabetes Mellitus
Objective The aim of this study is to evaluate whether diabetes mellitus (DM) is a risk factor for titanium fixture loss in bone-conduction devices (BCDs) because of osseointegration failure. Study Design Retrospective case study. Setting Tertiary referral center. Patients All patients who received a BCD at Nijmegen between January 1, 1988, and December 31, 2007, were analyzed. The analyses were performed on 833 patients (993 implants) and a subpopulation of patients aged 40 years or older consisting of 641 patients (739 implants). Methods Patients received a questionnaire asking about the presence of DM at the time of implantation. Data concerning implant loss were retrieved from medical records and the Nijmegen BCD database. Results The total survival rate of the BCD implant in this population was 90.6%. The prevalence of DM was 9.3%. In the subpopulation of patients aged 40 years or older, the non-DM group lost 5.1% of their implants versus 14% of Type 2 DM patients, a statistically significantly difference (p = 0.003). Spontaneous loss, loss due to a Grade 4 Holgers skin reaction, and trauma accounted for 2.2% versus 4.7% (p = 0.13), 0.5% versus 2.3% (p = 0.1), and 0.6% versus 4.7% (p = 0.007), respectively, of implant losses in non-DM versus Type 2 DM patients. Conclusion The prevalence of DM among the Nijmegen BCD population is higher than the general Dutch prevalence. A statistically significantly higher implant loss was observed during the study period for Type 2 DM patients than non-DM BCD wearers.